HomeAI · summaries
Storia in 3 fonti
Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drug
Boulevard Bio launches with $65M from Deerfield Management, advancing BLVD101 (IgAN bispecific), BLVD201 from METiS TechBio, and BLVD301. CEO Mahesh Karande seeks additional investors.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Boulevard starts up with $65M to pursue targeted autoimmune drugs
Co-founded by pioneering researcher Georg Schett and ex-Sanofi CSO Frank Nestle, the startup is advancing a trio of multifaceted antibodies with the potential to treat several…
- ·
endpoints.news
Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drug
Boulevard Bio launches with $65M from Deerfield Management, advancing BLVD101 (IgAN bispecific), BLVD201 from METiS TechBio, and BLVD301. CEO Mahesh Karande seeks additional…
